ACM
VINC

Altium Capital Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Altium Capital Management’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,381
Closed -$1.74M – 159
2021
Q3 		$1.74M Hold
5,381
– – 0.46% 83
2021
Q2 		$1.4M Buy
+5,381
New +$1.64M 0.32% 98
2021
Q1 		– Sell
-7,508
Closed -$3.14M – 143
2020
Q4 		$3.14M Buy
+7,508
New +$2.37M 1.17% 34

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Altium Capital Management's VINC Position: Q4 2021 in Review

Altium Capital Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2021, closing a stake of 5,381 shares — an estimated $1.74M sold.

Altium Capital Management first reported a position in VINC in Q4 2020 and held it in 3 quarters. The position peaked at $3.14M in Q4 2020. 55 funds tracked by Wall St. Rank hold VINC as of Q4 2021.

  • Altium Capital Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Altium Capital Management sold 5,381 Vincerx Pharma, Inc. Common Stock shares in Q4 2021, an estimated $1.74M.
  • Altium Capital Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Altium Capital Management's Vincerx Pharma, Inc. Common Stock position peaked at $3.14M in Q4 2020.
  • 55 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2021.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.